Investor Relations
At Aspire Pharma we continue to complement our robust organic growth with carefully selected acquisitions and strategic partnerships. These initiatives form a core component of our long-term growth strategy, enabling us to broaden our portfolio, enter new therapeutic areas and enhance our commercial and operational capabilities.
“Each strategic acquisition has brought a number of innovative products into our portfolio, which have strengthened our commitment to providing high-quality solutions to patients, as well as opened-up opportunities for new areas of growth in the UK and other geographic territories.”
Richard Condon
Aspire Pharma Chief Executive Officer
Partnership-led approach
Our partnership-led approach is focused on building scale and accelerating innovation with the ultimate goal of establishing Aspire as one of the largest and fastest-growing niche generic pharmaceutical companies in the UK and across Europe.
We remain focused on pursuing strategic opportunities that complement our existing strengths, support our long-term vision and deliver sustained value to our stakeholders.
A philosophy of M&A
In 2021 H.I.G. Capital Europe acquired a majority stake in Aspire Pharma Limited. Through continued investment Aspire has accelerated our strategic growth through a series of value enhancing acquisitions.
Morningside Pharmaceuticals (October 2022)
In October 2022, we completed the acquisitions of Morningside Pharmaceuticals, Morningside Healthcare and Morningside Healthcare India. These acquisitions contributed significantly to our strategy of expanding our global footprint, diversifying our product portfolio and enhancing our supply chain capabilities.
Cenoté Pharma (March 2024)
In March 2024, we acquired Cenoté Pharma, a recognised category specialist in carnitine deficiency treatments. This strategic move aligns with our focus on high-growth, niche therapeutic areas and reinforces our commitment to addressing unmet patient needs.,
Canute Pharma (October 2024)
In October 2024 we acquired the full asset portfolio of Canute Pharma. This acquisition deepened our presence in dermatology, adding further breadth and clinical relevance to our growing specialty care portfolio.
Contact our team
Aspire welcomes all types of business development opportunities.
If you have an idea, please get in touch:
Contact form
Phone
MAT-UK-COR-0033-2 | January 2026
